Bicara CEO‑in‑Waiting Trades 18,750 Shares in a 10b5‑1 Hedge, Selling Options at Higher Prices Ahead of 2027 Transition

Insider Activity Highlights a Strategic Shift at Bicara

Bicara Therapeutics Inc. (NASDAQ: BCTI) has entered a new chapter in its leadership trajectory, with President‑and‑COO Ryan Cohlhepp set to become CEO in January 2027. The recent Form 4 filing on August 10, 2026 shows Cohlhepp purchasing 18,750 shares under a Rule 10b5‑1 plan at $3.79 per share, while also selling 18,750 options and a block of 18,750 common shares at $27.98. The trade was executed amid a market price of $24.63, a modest uptick of 0.04 % that suggests the deal was likely driven by the pre‑planned trading strategy rather than opportunistic timing.

What Does This Mean for Investors? The dual buy‑sell pattern under a 10b5‑1 plan is typical for insiders who wish to hedge exposure while maintaining a long‑term commitment to the company. Cohlhepp’s purchase of roughly 1 % of the outstanding shares (post‑transaction holdings around 200,000 shares) signals confidence in Bicara’s long‑term value. Investors may interpret this as a positive endorsement of the upcoming CEO transition and the company’s Phase III FORTIFI‑HN01 study, which the filing notes remains on track. However, the simultaneous sale of options and shares at higher prices may raise concerns about potential profit‑taking ahead of the leadership change—an area that warrants close monitoring as the company progresses toward its 2027 CEO handover.

Cohlhepp’s Insider Profile A review of Cohlhepp’s historical trades shows a pattern of disciplined, rule‑based transactions. Since March 2026, he has repeatedly executed 10b5‑1 buys and sells of 18,750 shares at the $3.79 strike, with occasional larger sales at the market price (up to $30.35). His option activity—selling 18,750 options each month—reflects a systematic approach to managing his equity position. Over the past year, Cohlhepp has held roughly 200,000–210,000 shares, indicating a substantial, long‑term stake that aligns with his impending CEO responsibilities. His trading cadence suggests a focus on stability rather than speculative short‑term gains, which could be reassuring for shareholders anticipating a steady leadership transition.

Company‑Wide Insider Momentum While Cohlhepp’s moves are the most pronounced, other senior officers have also been active. Claire Mazumdar (CEO) and Ivan Hyep (CFO) each completed three transactions on August 10, 2026, balancing buys and sells across the $3.79–$28 range. This broader insider activity, combined with the company’s 115.86 % YTD share price gain and a 52‑week high of $30.99, paints a picture of a leadership group that is engaged with the market yet mindful of regulatory compliance. The high social‑media buzz (183.76 %) suggests heightened investor interest, possibly driven by the leadership announcement and the company’s emerging‑growth status.

Bottom Line Cohlhepp’s Rule 10b5‑1 purchase underscores a continued commitment to Bicara despite the immediate sale of options at higher prices. For investors, this signals confidence in the company’s trajectory and the upcoming CEO transition. The broader insider activity, coupled with a strong year‑to‑date performance, indicates that Bicara’s leadership team is actively managing its equity while steering the company toward a new executive horizon.